William (bill) Young
CLINICAL RESEARCH
Annexon Biosciences
New Zealand
Biography
Mr. Young joined Clarus Ventures in 2010 as a Venture Partner from Monogram Biosciences, a leader in personalized medicine, where he served as chief executive officer from 1999 through to the sale of the company to LabCorp in 2009. Mr. Young currently serves on the Board of Directors of BioMarin (NASDAQ:BMRN), Theravance (NASDAQ:TBPH), and Vertex (NASDAQ: VRTX) and Annexon Biosciences. Previously he was Chairman of the Board of Biogen IDEC (NASDAQ: BIIB). Prior to Monogram he was at Genentech since 1980 at positions of increasing responsibility, including chief operating officer responsible for all of the biotechnology company’s development, operations and commercial functions. Prior to Genentech Mr. Young was at Eli Lilly and Company for fourteen years. Mr. Young received his bachelor’s degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his leadership in research, development and manufacturing of recombinant proteins using recombinant DNA technology.
Research Interest
=
